Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
about
Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer MetabolismEmerging PSA-based tests to improve screeningRecent developments in multivitamin/mineral researchOverdiagnosis and overtreatment of prostate cancerManagement of low (favourable)-risk prostate cancerLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesLoss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Cancer incidence trends among Asian American populations in the United States, 1990-2008Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort.A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancerProstate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosureMen (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohortFocal therapy for prostate cancer: rationale and treatment opportunities.Focal therapy in the management of localized prostate cancer.Childhood body mass index and the risk of prostate cancer in adult men.Screening for prostate cancer: the debate continuesIncreasing detection of significant prostate cancer in younger men - ten year trends in prostate cancer risk profile in the Mid-West of Ireland.Evolution from active surveillance to focal therapy in the management of prostate cancer.Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies.Principles of cancer screening: lessons from history and study design issues.Cancer screening trials: nuts and bolts.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.From bench to bedside: the realities of reducing global prostate cancer disparity in black men.Simulation optimization of PSA-threshold based prostate cancer screening policies.Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.Prostate cancer susceptibility variants confer increased risk of disease progression.Reduced risk of prostate cancer in U.S. Men with AIDS.Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Patient perspective on watchful waiting/active surveillance for localized prostate cancer.The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer.Expected population impacts of discontinued prostate-specific antigen screening.Gleason 6 Prostate Cancer: Translating Biology into Population Health.What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?Cancer survivors in Switzerland: a rapidly growing population to care for.Men's perspectives on selecting their prostate cancer treatmentProstate cancer in East Asia: evolving trend over the last decade.New serum biomarkers for prostate cancer diagnosis.Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
P2860
Q26774456-52CA2802-C8B4-42BC-8ED5-AC16058066F0Q26828563-A6CA7436-8DC5-4512-A5DA-8D77247C791BQ26849381-92C994B0-8314-4C5F-BA5C-0E9D4D444469Q26859596-FFB40C25-6A4F-4E29-AD66-C44132B17E00Q26996501-165F9D5B-A998-4AF0-B5A7-A59DA11299F1Q28251617-B6833692-744D-48C3-AB2C-E99E0715D7EAQ30009388-F404AFBB-80BD-4030-91BD-C431A381306CQ30542355-0C730B84-0D2C-4236-A005-18DE30D61D54Q31016924-CE9331EC-86D2-44AD-B350-EEC62E3755AEQ33558289-C305AF8A-4192-4828-BF51-D4F5A9CAD734Q33599365-644CE17F-2CBF-4F8C-897E-C3835067F254Q33642527-D2246FB3-1B01-4E86-9152-C5F45831C40BQ33643656-D654E045-F9C0-4E04-87F3-0CA88A19457DQ33702259-1E893B55-441D-48E1-A736-805529DE77E4Q33790382-E81C20EA-C242-4B11-88A5-F560DA98709AQ33877451-9E6A558E-F5CD-4A70-8FB9-3037B8A28C42Q33885776-F883424C-8491-408A-892A-BE83A1B1AC4AQ33904126-7647ACA1-25E9-40E7-8852-6801AA4D4ACBQ33933490-8F98496B-3447-4E6C-8B1F-6015694289C1Q34014487-A6CA65AC-3D45-449E-B17D-2A49AD837C28Q34065705-770D86C0-9D30-417A-8A53-7BBDC4746E09Q34073143-F8596D01-2353-48A9-A6DB-677AE0FEBA6BQ34130128-79E414EA-29D4-49DE-BA15-080BD969960EQ34135132-9256CAA1-76FB-4C45-8552-37276DA526D1Q34149637-1F2DF88D-369B-4BFB-9E61-B545EC11B39AQ34160375-0D8D23A2-C36E-4D09-86FF-70E794EBB685Q34175836-95E3E973-B533-4658-8FE0-69E4CC05FF9DQ34292990-2F63ED03-33FE-4B37-BFD6-A753F7F287A9Q34344121-E5FD4379-5220-4E04-AC25-D18FE52976C8Q34387852-D59F1AFB-F214-4CBF-97EB-A242115011ADQ34419421-CB64EAF0-2752-47E9-9AD9-C084AF68B6D9Q34453917-F69F266D-9F1E-4457-8A35-04F96DAAC286Q34458237-EBEA58E1-178E-4586-9C79-8698D21B3D6AQ34470640-1ECD96D1-93A4-4E5C-AA01-CCD2BE7B0EBBQ34679360-2B5C5788-61AF-4601-B5A1-8FF700A54C35Q34771560-E4F11291-3C07-48A4-A83D-56D5937CD10AQ34817192-0DECF7C2-966D-46AC-9EFA-251A67996317Q34927940-1F75D5F8-FA86-4C6A-BAAC-30E006575846Q34939111-6C2BF512-FC12-4773-B3AC-305F3A8EC56FQ34975896-32674D91-EB95-46FA-8A03-CF4149E3242C
P2860
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@ast
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@en
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@nl
type
label
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@ast
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@en
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@nl
prefLabel
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@ast
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@en
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@nl
P2860
P3181
P356
P1476
Prostate cancer diagnosis and ...... c antigen screening: 1986-2005
@en
P2093
H Gilbert Welch
Peter C Albertsen
P2860
P304
P3181
P356
10.1093/JNCI/DJP278
P407
P577
2009-10-07T00:00:00Z